EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6 , reduces plasma iron and increases hepcidin levels of healthy volunteers

John B Porter iD, Alison Scrimgeour, Alberto Martinez, Leo James, Manuela Aleku, Rosamund Wilson, Martina Muckenthaler, Malcolm Boyce, Denise Wilkes, Ute Schaeper iD, Giles V Campion

American Journal of Hematology · 2023-09 · 98 (9) · 1425-1435

DOI: 10.1002/ajh.27015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, online erschienen am 27.07.2023. Verfasst von John B Porter und 10 weiteren Autor:innen. Beteiligte Einrichtung: University College Hospitals, London, UK. Hauptthemen laut MEDLINE: Iron, Anemia, Iron-Deficiency. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Silence Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SLN124, an N‐acetylgalactosamine conjugated 19‐mer short interfering RNA, is being developed to treat iron‐loading anemias (including beta‐thalassemia and myelodysplastic syndromes) and myeloproliferative neoplasms (polycythemia vera). Through hepatic targeting and silencing of the TMPRSS6 gene, SLN124 increases endogenous hepcidin synthesis. This is the first clinical report of an siRNA targeting a component of iron homeostasis. This first‐in‐human, phase 1 study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of SLN124 (1.0, 3.0, and 4.5 mg/kg) in healthy volunteers. Twenty‐four participants were randomized in three sequential cohorts of eight subjects, each to receive a single dose of either SLN124 or placebo (6:2 randomization), administered subcutaneously. There were no serious or severe adverse events, or discontinuations due to adverse events, and most treatment‐emergent adverse events were mild, including transient mild injection site reactions, resolving without intervention. SLN124 was rapidly absorbed, with a median t max of 4–5 h across all treatment groups, and largely eliminated from plasma by 48 h. Plasma concentrations increased in a greater than dose proportional fashion between treatment groups. In all SLN124 groups, a dose‐related effect was observed across iron metabolism markers, and across erythroid markers, SLN124 resulted in increased plasma hepcidin levels, peaking around Day 29, and consequent dose‐related sustained reductions in plasma iron and transferrin saturation with decreased reticulocyte production, MCHC, and MCV. Results suggest duration of action lasting up to 56 days after a single SLN124 dose, on hepcidin and hematological parameters of iron metabolism (serum iron and TSAT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IronAnemia, Iron-DeficiencyHumansHepcidinsRNA, Small InterferingHealthy VolunteersDouble-Blind Method

Substanzen

IronHepcidinsRNA, Small Interfering

Autor:innen und Institutionen

  • University College Hospitals, London, UK.
  • Silence Therapeutics PLC, London, UK.
  • Dr Leo James Ltd, Winchester, UK.
  • Silence Therapeutics GmbH, Berlin, Germany.
  • Spica Consultants Ltd, Marlborough, UK.
  • Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: John B Porter, Ute Schaeper

Förderung

  • Silence Therapeutics

Zitieren

APA

Porter, J. B., Scrimgeour, A., Martinez, A., James, L., Aleku, M., Wilson, R., Muckenthaler, M., Boyce, M., Wilkes, D., Schaeper, U., & Campion, G. V. (2023). SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6 , reduces plasma iron and increases hepcidin levels of healthy volunteers. American Journal of Hematology, 98(9), 1425-1435. https://doi.org/10.1002/ajh.27015

Vancouver

Porter JB, Scrimgeour A, Martinez A, James L, Aleku M, Wilson R, et al. SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6 , reduces plasma iron and increases hepcidin levels of healthy volunteers. American Journal of Hematology. 2023;98(9):1425-1435. doi:10.1002/ajh.27015

BibTeX
@article{Porter2023,
  author = {Porter, John B and Scrimgeour, Alison and Martinez, Alberto and James, Leo and Aleku, Manuela and Wilson, Rosamund and Muckenthaler, Martina and Boyce, Malcolm and Wilkes, Denise and Schaeper, Ute and Campion, Giles V},
  title = {SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6 , reduces plasma iron and increases hepcidin levels of healthy volunteers},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {9},
  pages = {1425--1435},
  doi = {10.1002/ajh.27015}
}
Kostenlos starten →